Menu

Genetic Mutation in Amish Linked to Longer Life

Mutations in both copies of SERPINE1 can result in blood clotting disorders, but carriers might enjoy longer lifespan and health benefits. 

Nov 16, 2017
Katarina Zimmer

FLICKR, TED VAN PELTA genetic mutation in an Amish community in Indiana that can cause fatal blood clotting has been linked to longevity and protection against diabetes, according to a study published in Science Advances this week (November 15).

Previous research has shown that the gene in question, SERPINE1, produces a protein that can promote aging in mice. Levels of the protein, called plasminogen activator inhibitor type 1 (PAI-1), are higher in patients with diabetes, obesity, or cardiovascular disease. PAI-1 is also known to play an important role in blood clotting, and people with two defect copies of SERPINE1 suffer from blood clotting disorders, Science reported.

But having one mutated copy of the gene may actually prove beneficial, according to the new study. Using death records to trace back facility histories in an Indiana Amish community, the researchers found that people who had one defective copy of SERPINE1 had a median lifespan of 85 years—10 years longer than people who had two intact copies. The scientists also found that people with one mutated copy tended to have longer telomeres, as well as 30 percent lower insulin levels when fasting, which is considered indicative of slower aging. Additionally, none of these people developed type 2 diabetes, compared with 7 percent of people with two intact copies of the gene.

“The carriers appear to be completely protected from diabetes,” coauthor Douglas Vaughan of Northwestern University told the New Scientist.

Geriatrician Nir Barzilai of Albert Einstein College of Medicine in New York City is skeptical of the link to lifespan, however. SERPINE1 is “not convincingly a longevity gene,” Barzilai, who was not involved in the research, told Science.  

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.